UMB Bank n.a. Has $46.19 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

UMB Bank n.a. lessened its holdings in Johnson & Johnson (NYSE:JNJ) by 1.6% in the fourth quarter, Holdings Channel reports. The institutional investor owned 319,400 shares of the company’s stock after selling 5,062 shares during the period. UMB Bank n.a.’s holdings in Johnson & Johnson were worth $46,192,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Providence Capital Advisors LLC lifted its position in shares of Johnson & Johnson by 12.4% in the 2nd quarter. Providence Capital Advisors LLC now owns 40,909 shares of the company’s stock worth $5,979,000 after purchasing an additional 4,500 shares during the period. Cheviot Value Management LLC raised its stake in Johnson & Johnson by 9.4% during the second quarter. Cheviot Value Management LLC now owns 144,825 shares of the company’s stock worth $21,168,000 after buying an additional 12,488 shares during the last quarter. Marshall Wace LLP lifted its holdings in Johnson & Johnson by 506.9% in the second quarter. Marshall Wace LLP now owns 3,884,962 shares of the company’s stock valued at $567,826,000 after buying an additional 3,244,862 shares during the period. Distillate Capital Partners LLC acquired a new stake in Johnson & Johnson during the 2nd quarter worth about $50,013,000. Finally, Gateway Advisory LLC raised its position in shares of Johnson & Johnson by 240.0% in the 2nd quarter. Gateway Advisory LLC now owns 16,780 shares of the company’s stock worth $2,453,000 after acquiring an additional 11,844 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms recently commented on JNJ. Citigroup decreased their target price on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. StockNews.com downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 17th. Royal Bank of Canada boosted their target price on shares of Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research report on Wednesday, October 16th. Wolfe Research initiated coverage on shares of Johnson & Johnson in a research note on Friday, November 15th. They issued an “outperform” rating and a $190.00 price target for the company. Finally, Barclays cut their price objective on shares of Johnson & Johnson from $160.00 to $159.00 and set an “equal weight” rating on the stock in a research report on Tuesday. Eight analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $173.27.

Insiders Place Their Bets

In other news, Director Mark A. Weinberger bought 1,000 shares of the company’s stock in a transaction on Thursday, December 12th. The shares were purchased at an average price of $147.22 per share, with a total value of $147,220.00. Following the transaction, the director now directly owns 1,000 shares in the company, valued at $147,220. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $148.10 on Wednesday. The company has a market cap of $356.57 billion, a PE ratio of 21.43, a price-to-earnings-growth ratio of 2.39 and a beta of 0.51. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $168.85. The business has a 50 day moving average price of $148.35 and a 200-day moving average price of $156.11.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.35%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 71.78%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.